Abstract
The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.
| Original language | Italian |
|---|---|
| Pages (from-to) | 179-183 |
| Number of pages | 5 |
| Journal | Giornale Italiano di Endoscopia Digestiva |
| Volume | 36 |
| Issue number | 3 |
| Publication status | Published - Sep 2013 |
Fingerprint
ASJC Scopus subject areas
- Gastroenterology
- Radiology Nuclear Medicine and imaging
Cite this
I farmaci biologici nelle malattie infiammatorie croniche intestinali. / Spina, Luisa; Pastorelli, Luca; De Nucci, Germana; Cavallaro, Flaminia; Tontini, Gian Eugenio; Munizio, Nadia; Vecchi, Maurizio.
In: Giornale Italiano di Endoscopia Digestiva, Vol. 36, No. 3, 09.2013, p. 179-183.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - I farmaci biologici nelle malattie infiammatorie croniche intestinali
AU - Spina, Luisa
AU - Pastorelli, Luca
AU - De Nucci, Germana
AU - Cavallaro, Flaminia
AU - Tontini, Gian Eugenio
AU - Munizio, Nadia
AU - Vecchi, Maurizio
PY - 2013/9
Y1 - 2013/9
N2 - The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.
AB - The introduction of biolologic therapy (infliximab, adalimumab) has led to a deep transformation in the management of inflammatory bowel disease (Crohn's disease and ulcerative colitis). Despite their proven efficacy, open issues still remain about their long term safety profile and the optimization of their use; particularly as far as the personalization of the therapy is concerned.
KW - Adalimumab
KW - Crohn's disease
KW - Infliximab
KW - Ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=84886010950&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886010950&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:84886010950
VL - 36
SP - 179
EP - 183
JO - Giornale Italiano di Endoscopia Digestiva
JF - Giornale Italiano di Endoscopia Digestiva
SN - 0394-0225
IS - 3
ER -